Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Early-Stage Technologies In Brief

This article was originally published in The Gray Sheet

Executive Summary

Biowave DeepTreat: Initial 510(k) clearance is likely in second quarter of 2004 for pain-blocking technology, Norwalk, Conn. firm tells potential investors during recent Medtech Insight conference in Boston. The product is similar to implanted neuromodulation devices, but can be done in a physician's office at a lower cost, according to Biowave. In clinical studies of the device, which incorporates a disposable, percutaneous electrode array with 3,600 microneedles that deliver an electric field signal into deep tissue, patients report an average 80% reduction in pain at one hour post-treatment. DeepTreat thus reduces the need for painkillers, the company says. The product is reimbursed at $125-$320 per treatment, and a CPT code is expected as early as Q1 2004. Biowave is seeking $7 mil. to complete development...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT019325

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel